New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
Go back to New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 228.69 +1.09 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $227.60 | 52 Week High | $333.65 | |||
| Open | $225.87 | 52 Week Low | $223.02 | |||
| Day High | $230.49 | P/E | 29.28 | |||
| Day Low | $225.51 | EPS | $7.81 | |||
| Volume | 1,332,336 | |||||
